[{"address1": "9390 Towne Centre Drive", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 779 3100", "website": "https://poseida.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.", "fullTimeEmployees": 350, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark J. Gergen J.D.", "age": 60, "title": "Executive Chairman of the Board", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 961797, "exercisedValue": 0, "unexercisedValue": 174418}, {"maxAge": 1, "name": "Dr. Kristin  Yarema Ph.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 711986, "exercisedValue": 0, "unexercisedValue": 61459}, {"maxAge": 1, "name": "Ms. Johanna M. Mylet CPA", "age": 35, "title": "Chief Financial Officer", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Loren  Wagner", "title": "Chief Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristin  Martin", "title": "Chief People & Administration Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Chapman", "title": "Senior VP of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harry J. Leonhardt Esq., J.D.", "age": 66, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 630233, "exercisedValue": 0, "unexercisedValue": 25579}, {"maxAge": 1, "name": "Dr. Devon J. Shedlock Ph.D.", "title": "Chief Scientific Officer of Cell Therapy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Portale", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  W. Winkelman J.D., Ph.D.", "title": "Senior VP & Chief Patent Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 2.86, "open": 9.27, "dayLow": 9.25, "dayHigh": 9.41, "regularMarketPreviousClose": 2.86, "regularMarketOpen": 9.27, "regularMarketDayLow": 9.25, "regularMarketDayHigh": 9.41, "beta": 0.536, "forwardPE": -5.1931705, "volume": 29530531, "regularMarketVolume": 29530531, "averageVolume": 487039, "averageVolume10days": 517600, "averageDailyVolume10Day": 517600, "bid": 9.35, "ask": 9.37, "bidSize": 500, "askSize": 100, "marketCap": 912759680, "fiftyTwoWeekLow": 1.87, "fiftyTwoWeekHigh": 9.41, "priceToSalesTrailing12Months": 6.050456, "fiftyDayAverage": 2.7844, "twoHundredDayAverage": 2.953675, "currency": "USD", "enterpriseValue": 130624968, "profitMargins": -0.40276, "floatShares": 64695334, "sharesOutstanding": 97465000, "sharesShort": 4394596, "sharesShortPriorMonth": 4539158, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0452, "heldPercentInsiders": 0.27642, "heldPercentInstitutions": 0.55759, "shortRatio": 9.15, "shortPercentOfFloat": 0.0626, "impliedSharesOutstanding": 97465000, "bookValue": 0.895, "priceToBook": 10.463687, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -60759000, "trailingEps": -0.63, "forwardEps": -1.68, "enterpriseToRevenue": 0.866, "enterpriseToEbitda": -2.291, "52WeekChange": 0.07924533, "SandP52WeekChange": 0.31449282, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PSTX", "underlyingSymbol": "PSTX", "shortName": "Poseida Therapeutics, Inc.", "longName": "Poseida Therapeutics, Inc.", "firstTradeDateEpochUtc": 1594387800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "291e20e1-54d3-33de-96cd-b23bf8be3533", "messageBoardId": "finmb_302863260", "gmtOffSetMilliseconds": -18000000, "currentPrice": 9.365, "targetHighPrice": 10.0, "targetLowPrice": 9.0, "targetMeanPrice": 9.5, "targetMedianPrice": 9.5, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 230852000, "totalCashPerShare": 2.369, "ebitda": -57017000, "totalDebt": 82727000, "quickRatio": 3.138, "currentRatio": 3.203, "totalRevenue": 150858000, "debtToEquity": 94.858, "revenuePerShare": 1.564, "returnOnAssets": -0.13112001, "returnOnEquity": -0.57627, "freeCashflow": -22237750, "operatingCashflow": -15023000, "revenueGrowth": 6.672, "grossMargins": -0.14298001, "ebitdaMargins": -0.37794998, "operatingMargins": 0.27516, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-26"}]